Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.66 |
| ▸ | RECQL | P46063 | 5/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.66 |
| ▸ | USP2 | O75604 | 3/20 | 0.66 |
| ▸ | LCK | P06239 | 3/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.66 |
| ▸ | HTR2A | P28223 | 2/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.66 |
| ▸ | FYN | P06241 | 2/20 | 0.66 |
| ▸ | EGFR | P00533 | 1/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.66 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.66 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | POLB | P06746 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5691448 | 1.00 | KDM6B (1.00) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL29869020 | 1.00 | KDM6B (1.00) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL29350434 | 1.00 | KDM6B (1.00) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL18469325 | 1.00 | KDM6B (1.00) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL29085430 | 0.98 | KDM6B (0.96) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL6535013 | 0.98 | KDM6B (0.96) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL29085429 | 0.98 | KDM6B (0.96) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL19369736 | 0.85 | KDM6B (0.73) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL19369740 | 0.85 | KDM6B (0.73) | KDM6BKDM4EHSD17B10TDP1ALOX15 | |
| SCHEMBL490593 | 0.84 | KDM6B (0.72) | KDM6BKDM4EHSD17B10TDP1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 602 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118890971-A | Steviol glycoside concentrate and highly soluble steviol glycoside | 嘉吉公司 | 2024-11-01 | — | — | CN | claimed |
| US-12097231-B2 | Steviol glycoside compositions with reduced surface tension | CARGILL, INCORPORATED (US) | 2024-09-24 | — | — | US | claimed |
| CN-113710105-B | Steviol glycoside solubility enhancers | 嘉吉公司 | 2024-05-28 | — | — | CN | claimed |
| US-20240074481-A1 | CAPSULE-CONTAINING POUCHED PRODUCT FOR ORAL USE | REYNOLDS TOBACCO CO R (US) | 2024-03-07 | — | — | US | claimed |
| US-20240050506-A1 | STEVIOL GLYCOSIDE COMPOSITIONS WITH REDUCED SURFACE TENSION | CARGILL, INCORPORATED (US) | 2024-02-15 | — | — | US | claimed |
| WO-2023177970-A1 | STEVIOL GLYCOSIDE CONCENTRATES AND HIGHLY SOLUBLE STEVIOL GLYCOSIDES | CARGILL, INCORPORATED (US) | 2023-09-21 | — | — | WO | claimed |
| US-11717549-B2 | Steviol glycoside solubility enhancers | CARGILL, INCORPORATED (US) | 2023-08-08 | — | — | US | claimed |
| CN-116492359-A | Composition containing glycosylated puerarin and preparation method and application thereof | 南方医科大学珠江医院 | 2023-07-28 | — | — | CN | claimed |
| US-11701400-B2 | Steviol glycoside compositions with reduced surface tension | CARGILL, INCORPORATED (US) | 2023-07-18 | — | — | US | claimed |
| CN-115403653-A | D (+) -beta- (3, 4-dihydroxyphenyl) -lactyl-Pro-Ala-Lys, synthesis and application thereof | 首都医科大学 | 2022-11-29 | — | — | CN | claimed |
| WO-2004037180-A2 | COMPOSITIONS THAT TREAT OR INHIBIT PATHOLOGICAL CONDITIONS ASSOCIATED WITH INFLAMMATORY RESPONSE | METAPROTEOMICS, LLC (US) | 2004-05-06 | — | — | WO | claimed |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| US-20030138537-A1 | Methods of preparing improved water-soluble extracts containing antioxidants and uses thereof | HAUSER, INC. A DELAWARE CORPORATION | 2003-07-24 | — | — | US | claimed |
| WO-2003053148-A1 | METHODS OF PREPARING IMPROVED WATER-SOLUBLE EXTRACTS CONTAINING ANTIOXIDANTS AND USES THEREOF | HAUSER, INC. (US) | 2003-07-03 | — | — | WO | claimed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | claimed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | claimed |
| US-5011775-A | Enzymatic process for the preparation of rosmarinic acid | FORSCHUNGSZENTRUM JUELICH GMBH (DE) | 1991-04-30 | — | — | US | claimed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | claimed |
| US-4363815-A | Alpha hydroxyacids, alpha ketoacids and their use in treating skin conditions | YU RUEY J | 1982-12-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701400-B2 | Steviol glycoside compositions with reduced surface tension | STT3A, SIGLEC7, STT3B | KDM6B 4245/4885KDM4E 4391/4885HSD17B10 473/4885 |
| US-11717549-B2 | Steviol glycoside solubility enhancers | SI, TAS2R7, TAS2R31 | KDM6B 2458/4885KDM4E 3664/4885HSD17B10 827/4885 |
| US-12097231-B2 | Steviol glycoside compositions with reduced surface tension | STT3A, SIGLEC7, STT3B | KDM6B 4245/4885KDM4E 4391/4885HSD17B10 473/4885 |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | GLS, APEH, GGH | KDM6B 1576/4885KDM4E 1203/4885HSD17B10 268/4885 |
| US-20240050506-A1 | STEVIOL GLYCOSIDE COMPOSITIONS WITH REDUCED SURFACE TENSION | STT3A, SIGLEC7, STT3B | KDM6B 4245/4885KDM4E 4391/4885HSD17B10 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.